Bioequivalence Study of Mirabegron From Bladogra 25 mg Extended Release Tablets (Multi-Apex for Pharmaceutical Industries, Egypt) Versus Myrbetriq 25 mg Extended Release Tablets (Marketed by Astellas Pharma US, Inc, Product of Japan)

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

January 20, 2020

Primary Completion Date

March 2, 2020

Study Completion Date

May 11, 2020

Conditions

Healthy

Interventions

DRUG

Bladogra

1 tablet contains 25 mg Mirabegron

DRUG

Myrbetriq (first dosing)

1 tablet contains 25 mg Mirabegron

DRUG

Myrbetriq (second dosing)

1 tablet contains 25 mg Mirabegron

Trial Locations (1)

Genuine Research Center GRC, Cairo